Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Renal cryoablation - does deep endophytic ablation affect the renal collecting system?

Makki A, Aastrup MB, Vinter H, Ginnerup B, Graumann O, Borre M, Nielsen TK.

Scand J Urol. 2020 Feb;54(1):33-39. doi: 10.1080/21681805.2019.1702094. Epub 2019 Dec 16.

PMID:
31842655
2.

Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study.

Skriver C, Dehlendorff C, Borre M, Brasso K, Larsen SB, Tjønneland A, Pottegård A, Hallas J, Sørensen HT, Friis S.

Cancer Causes Control. 2020 Feb;31(2):139-151. doi: 10.1007/s10552-019-01252-5. Epub 2019 Dec 10.

PMID:
31823168
3.

Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata).

Nguyen-Nielsen M, Møller H, Tjønneland A, Borre M.

Cancer Epidemiol. 2020 Feb;64:101623. doi: 10.1016/j.canep.2019.101623. Epub 2019 Nov 21.

PMID:
31760356
4.

Epigenetic silencing of MEIS2 in prostate cancer recurrence.

Nørgaard M, Haldrup C, Bjerre MT, Høyer S, Ulhøi B, Borre M, Sørensen KD.

Clin Epigenetics. 2019 Oct 22;11(1):147. doi: 10.1186/s13148-019-0742-x.

5.

Internet-delivered mindfulness-based cognitive therapy for anxiety and depression in cancer survivors: A randomized controlled trial.

Nissen ER, O'Connor M, Kaldo V, Højris I, Borre M, Zachariae R, Mehlsen M.

Psychooncology. 2020 Jan;29(1):68-75. doi: 10.1002/pon.5237. Epub 2019 Nov 1.

6.

Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial.

Bjerre ED, Petersen TH, Jørgensen AB, Johansen C, Krustrup P, Langdahl B, Poulsen MH, Madsen SS, Østergren PB, Borre M, Rørth M, Brasso K, Midtgaard J.

PLoS Med. 2019 Oct 1;16(10):e1002936. doi: 10.1371/journal.pmed.1002936. eCollection 2019 Oct.

7.

Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells.

Laursen EB, Fredsøe J, Schmidt L, Strand SH, Kristensen H, Rasmussen AKI, Daugaard TF, Mouritzen P, Høyer S, Kristensen G, Stroomberg HV, Brasso K, Røder MA, Borre M, Sørensen KD.

Am J Pathol. 2019 Dec;189(12):2377-2388. doi: 10.1016/j.ajpath.2019.08.007. Epub 2019 Sep 17.

8.

Resistance Training Increases Muscle Strength and Muscle Size in Patients With Liver Cirrhosis.

Aamann L, Dam G, Borre M, Drljevic-Nielsen A, Overgaard K, Andersen H, Vilstrup H, Aagaard NK.

Clin Gastroenterol Hepatol. 2019 Aug 5. pii: S1542-3565(19)30847-X. doi: 10.1016/j.cgh.2019.07.058. [Epub ahead of print]

PMID:
31394282
9.

Use of biologically based complementary medicines in patients with neuroendocrine tumors.

Borre M, Dam GA, Grønbaek H.

Scand J Gastroenterol. 2019 Aug;54(8):998-1002. doi: 10.1080/00365521.2019.1646799. Epub 2019 Aug 1.

PMID:
31368373
10.

The relationship between tumor aggressiveness and cholinergic PET imaging in prostate cancer tissue. A proof-of-concept study.

Nielsen MM, Tolbod LP, Borre M, Høyer S, Harms HJ, Sørensen J, Frøkiær J, Borghammer P.

Am J Nucl Med Mol Imaging. 2019 Jun 15;9(3):185-192. eCollection 2019.

11.

Repeatability of tumor blood flow quantification with 82Rubidium PET/CT in prostate cancer - a test-retest study.

Jochumsen MR, Bouchelouche K, Nielsen KB, Frøkiær J, Borre M, Sörensen J, Tolbod LP.

EJNMMI Res. 2019 Jul 4;9(1):58. doi: 10.1186/s13550-019-0529-2.

12.

Pathophysiology and management of diabetic gastroenteropathy.

Meldgaard T, Keller J, Olesen AE, Olesen SS, Krogh K, Borre M, Farmer A, Brock B, Brock C, Drewes AM.

Therap Adv Gastroenterol. 2019 Jun 17;12:1756284819852047. doi: 10.1177/1756284819852047. eCollection 2019. Review.

13.

Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.

Thomsen FB, Røder MA, Jakobsen H, Langkilde NC, Borre M, Jakobsen EB, Frey A, Lund L, Lunden D, Dahl C, Brasso K.

Clin Genitourin Cancer. 2019 Aug;17(4):e814-e821. doi: 10.1016/j.clgc.2019.05.005. Epub 2019 May 21.

PMID:
31196798
14.

A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy.

Strand SH, Bavafaye-Haghighi E, Kristensen H, Rasmussen AK, Hoyer S, Borre M, Mouritzen P, Besenbacher S, Orntoft TF, Sorensen KD.

Int J Cancer. 2019 Dec 15;145(12):3445-3452. doi: 10.1002/ijc.32427. Epub 2019 Jun 7.

PMID:
31125115
15.

Home-based 'exergaming' was safe and significantly improved 6-min walking distance in patients with prostate cancer: a single-blinded randomised controlled trial.

Villumsen BR, Jorgensen MG, Frystyk J, Hørdam B, Borre M.

BJU Int. 2019 Apr 22. doi: 10.1111/bju.14782. [Epub ahead of print]

PMID:
31012238
16.

A Single Urine Sodium Measurement May Validly Estimate 24-hour Urine Sodium Excretion in Patients With an Ileostomy.

Pedersen AKN, Rud C, Wilkens TL, Borre M, Andersen JR, Dahlerup JF, Hvas CL.

JPEN J Parenter Enteral Nutr. 2020 Feb;44(2):246-255. doi: 10.1002/jpen.1593. Epub 2019 Apr 15.

17.

A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine.

Fredsøe J, Rasmussen AKI, Mouritzen P, Borre M, Ørntoft T, Sørensen KD.

Int J Cancer. 2019 Nov 1;145(9):2558-2567. doi: 10.1002/ijc.32296. Epub 2019 Apr 8.

PMID:
30903800
18.

Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer.

Bjerre MT, Strand SH, Nørgaard M, Kristensen H, Rasmussen AK, Mortensen MM, Fredsøe J, Mouritzen P, Ulhøi B, Ørntoft T, Borre M, Sørensen KD.

Int J Mol Sci. 2019 Mar 7;20(5). pii: E1173. doi: 10.3390/ijms20051173.

19.

Causes of death in men with prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata).

Nguyen-Nielsen M, Møller H, Tjønneland A, Borre M.

Cancer Epidemiol. 2019 Apr;59:249-257. doi: 10.1016/j.canep.2019.02.017. Epub 2019 Mar 9.

PMID:
30861444
20.

Long-term Somatic Disease Risk in Adult Danish Cancer Survivors.

Kjaer TK, Andersen EAW, Winther JF, Bidstrup PE, Borre M, Møller H, Larsen SB, Johansen C, Dalton SO.

JAMA Oncol. 2019 Apr 1;5(4):537-545. doi: 10.1001/jamaoncol.2018.7192. Erratum in: JAMA Oncol. 2019 Apr 1;5(4):579.

21.

Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis: A Nationwide Cohort Study.

Skriver C, Dehlendorff C, Borre M, Brasso K, Larsen SB, Dalton SO, Nørgaard M, Pottegård A, Hallas J, Sørensen HT, Friis S.

Ann Intern Med. 2019 Apr 2;170(7):443-452. doi: 10.7326/M17-3085. Epub 2019 Mar 5.

PMID:
30831581
22.

5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors.

Kristensen G, Strand SH, Røder MA, Berg KD, Toft BG, Høyer S, Borre M, Sørensen KD, Brasso K.

Int J Mol Sci. 2019 Feb 27;20(5). pii: E1025. doi: 10.3390/ijms20051025.

23.

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW.

J Clin Oncol. 2019 May 1;37(13):1051-1061. doi: 10.1200/JCO.18.02031. Epub 2019 Feb 28.

PMID:
30817251
24.

Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine.

Fredsøe J, Rasmussen AKI, Laursen EB, Cai Y, Howard KA, Pedersen BG, Borre M, Mouritzen P, Ørntoft T, Sørensen KD.

Clin Chem. 2019 Apr;65(4):540-548. doi: 10.1373/clinchem.2018.296681. Epub 2019 Feb 6.

PMID:
30728149
25.

Clinical evaluation and treatment of chronic bowel symptoms following cancer in the colon and pelvic organs.

Larsen HM, Borre M, Christensen P, Mohr Drewes A, Laurberg S, Krogh K, Fassov J.

Acta Oncol. 2019 May;58(5):776-781. doi: 10.1080/0284186X.2018.1562211. Epub 2019 Jan 30.

PMID:
30698052
26.

Quantitative Tumor Perfusion Imaging with 82Rb PET/CT in Prostate Cancer: Analytic and Clinical Validation.

Jochumsen MR, Tolbod LP, Pedersen BG, Nielsen MM, Høyer S, Frøkiær J, Borre M, Bouchelouche K, Sörensen J.

J Nucl Med. 2019 Aug;60(8):1059-1065. doi: 10.2967/jnumed.118.219188. Epub 2019 Jan 25.

PMID:
30683762
27.

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2019 Feb;51(2):363. doi: 10.1038/s41588-018-0330-6.

PMID:
30622367
28.

Football Compared with Usual Care in Men with Prostate Cancer (FC Prostate Community Trial): A Pragmatic Multicentre Randomized Controlled Trial.

Bjerre ED, Brasso K, Jørgensen AB, Petersen TH, Eriksen AR, Tolver A, Christensen JF, Poulsen MH, Madsen SS, Østergren PB, Borre M, Krustrup P, Johansen C, Rørth M, Midtgaard J.

Sports Med. 2019 Jan;49(1):145-158. doi: 10.1007/s40279-018-1031-0.

29.

Non-invasive quantification of tumor blood flow in prostate cancer using 15O-H2O PET/CT.

Tolbod LP, Nielsen MM, Pedersen BG, Høyer S, Harms HJ, Borre M, Borghammer P, Bouchelouche K, Frøkiær J, Sørensen J.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):292-302. eCollection 2018.

30.

Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases.

Schmidt L, Møller M, Haldrup C, Strand SH, Vang S, Hedegaard J, Høyer S, Borre M, Ørntoft T, Sørensen KD.

Br J Cancer. 2018 Dec;119(12):1527-1537. doi: 10.1038/s41416-018-0321-5. Epub 2018 Nov 19.

31.

[Prostate cancer - screening and early detection].

Borre M.

Ugeskr Laeger. 2018 Nov 12;180(46). pii: V06180418. Danish.

PMID:
30417812
32.

An iso-osmolar oral supplement increases natriuresis and does not increase stomal output in patients with an ileostomy: A randomised, double-blinded, active comparator, crossover intervention study.

Rud C, Pedersen AKN, Wilkens TL, Borre M, Andersen JR, Moeller HB, Dahlerup JF, Hvas CL.

Clin Nutr. 2019 Oct;38(5):2079-2086. doi: 10.1016/j.clnu.2018.10.014. Epub 2018 Oct 24.

PMID:
30396772
33.

Heterozygous loss-of-function variants of MEIS2 cause a triad of palatal defects, congenital heart defects, and intellectual disability.

Verheije R, Kupchik GS, Isidor B, Kroes HY, Lynch SA, Hawkes L, Hempel M, Gelb BD, Ghoumid J, D'Amours G, Chandler K, Dubourg C, Loddo S, Tümer Z, Shaw-Smith C, Nizon M, Shevell M, Van Hoof E, Anyane-Yeboa K, Cerbone G, Clayton-Smith J, Cogné B, Corre P, Corveleyn A, De Borre M, Hjortshøj TD, Fradin M, Gewillig M, Goldmuntz E, Hens G, Lemyre E, Journel H, Kini U, Kortüm F, Le Caignec C, Novelli A, Odent S, Petit F, Revah-Politi A, Stong N, Strom TM, van Binsbergen E; DDD study, Devriendt K, Breckpot J.

Eur J Hum Genet. 2019 Feb;27(2):278-290. doi: 10.1038/s41431-018-0281-5. Epub 2018 Oct 5.

34.

Active Surveillance for Localized Prostate Cancer: Nationwide Observational Study.

Thomsen FB, Jakobsen H, Langkilde NC, Borre M, Jakobsen EB, Frey A, Lund L, Lunden D, Dahl C, Helgstrand JT, Brasso K.

J Urol. 2019 Mar;201(3):520-527. doi: 10.1016/j.juro.2018.09.045.

PMID:
30240689
35.

Regional variation in surgery for pancreatic cancer in Denmark 2011-2015.

Wennervaldt K, Kejs AM, Lipczak H, Bartels P, Borre M, Fristrup CW, Kehlet H.

Dan Med J. 2018 Sep;65(9). pii: A5503.

PMID:
30187862
36.

Robot-assisted laparoscopic cystectomy with intracorporeal urinary diversion vs. open mini-laparotomy cystectomy: evaluation of surgical inflammatory response and immunosuppressive ability of CO2-pneumoperitoneum in an experimental porcine study.

Kingo PS, Rasmussen TM, Jakobsen LK, Palmfeldt J, Nørregaard R, Borre M, Jensen JB.

Scand J Urol. 2018 Aug;52(4):249-255. doi: 10.1080/21681805.2018.1484508. Epub 2018 Sep 6.

PMID:
30185097
37.

Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.

Storebjerg TM, Strand SH, Høyer S, Lynnerup AS, Borre M, Ørntoft TF, Sørensen KD.

Clin Epigenetics. 2018 Aug 7;10(1):105. doi: 10.1186/s13148-018-0540-x.

38.

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.

Attard G, Borre M, Gurney H, Loriot Y, Andresen-Daniil C, Kalleda R, Pham T, Taplin ME; PLATO collaborators.

J Clin Oncol. 2018 Sep 1;36(25):2639-2646. doi: 10.1200/JCO.2018.77.9827. Epub 2018 Jul 20.

39.

Scandinavian Prostate Cancer Patients' Sexual Problems and Satisfaction With Their Sex Life Following Anti-Cancer Treatment.

Martin Hald G, Dahl Pind M, Borre M, Lange T.

Sex Med. 2018 Sep;6(3):210-216. doi: 10.1016/j.esxm.2018.06.002. Epub 2018 Jul 13.

40.

Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.

Schmidt L, Fredsøe J, Kristensen H, Strand SH, Rasmussen A, Høyer S, Borre M, Mouritzen P, Ørntoft T, Sørensen KD.

Ann Oncol. 2018 Sep 1;29(9):2003-2009. doi: 10.1093/annonc/mdy243.

41.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

42.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11. Erratum in: Nat Genet. 2019 Feb;51(2):363.

43.

Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.

Haldrup C, Pedersen AL, Øgaard N, Strand SH, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Mol Oncol. 2018 Apr;12(4):545-560. doi: 10.1002/1878-0261.12183. Epub 2018 Mar 13.

44.

Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study.

Kirkegaard P, Edwards A, Nielsen TLO, Ørntoft TF, Sørensen KD, Borre M, Bro F.

BMC Fam Pract. 2018 Feb 17;19(1):32. doi: 10.1186/s12875-018-0717-6.

45.

Soluble HER3 predicts survival in bladder cancer patients.

Memon AA, Gilliver SC, Borre M, Sundquist J, Sundquist K, Nexo E, Sorensen BS.

Oncol Lett. 2018 Feb;15(2):1783-1788. doi: 10.3892/ol.2017.7470. Epub 2017 Nov 22.

46.

Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.

Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L; Investigators of the Scandinavian Prostate Cancer Study Number 12.

Eur Urol. 2018 Jun;73(6):870-876. doi: 10.1016/j.eururo.2018.01.012. Epub 2018 Feb 1.

PMID:
29395502
47.

Nutritional status and nutritional risk in patients with neuroendocrine tumors.

Borre M, Dam GA, Knudsen AW, Grønbaek H.

Scand J Gastroenterol. 2018 Mar;53(3):284-292. doi: 10.1080/00365521.2018.1430848. Epub 2018 Jan 26.

PMID:
29373941
48.

Reply to M. Nayan et al.

Larsen SB, Dehlendorff C, Skriver C, Dalton SO, Jespersen CG, Borre M, Brasso K, Nørgaard M, Johansen C, Sørensen HT, Hallas J, Friis S.

J Clin Oncol. 2018 Feb 20;36(6):629-630. doi: 10.1200/JCO.2017.76.7186. Epub 2017 Dec 20. No abstract available.

PMID:
29261443
49.

Multi-parametric magnetic resonance imaging monitoring patients in active surveillance for prostate cancer: a prospective cohort study.

Elkjær MC, Andersen MH, Høyer S, Pedersen BG, Borre M.

Scand J Urol. 2018 Feb;52(1):8-13. doi: 10.1080/21681805.2017.1409265. Epub 2017 Dec 7.

PMID:
29212392
50.

Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.

Nørgaard M, Haldrup C, Storebjerg TM, Vestergaard EM, Wild PJ, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Int J Mol Sci. 2017 Sep 20;18(9). pii: E2017. doi: 10.3390/ijms18092017.

Supplemental Content

Support Center